Response to Gomez Et Al.'s Letter to the Editor Regarding: "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants"

Overview

Journal Infect Dis Ther

Specialty Infectious Diseases

Date 2022 May 16

PMID 35575973

Authors

Johnna Perdrizet

Emily Horn

Winniefer Nua

Judith Perez-Peralta

Jennifer Nailes

Jaime Santos

Anna Ong-Lim

Affiliations

Soon will be listed here.

References

Wilson M, Wasserman M, Jadavji T, Postma M, Breton M, Peloquin F . Response to McGirr et al.'s Comment on "Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada". Infect Dis Ther. 2018; 7(4):539-543. PMC: 6249185. DOI: 10.1007/s40121-018-0221-2. View

Ansaldi F, Pugh S, Amicizia D, Di Virgilio R, Trucchi C, Orsi A . Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy. Pathogens. 2020; 9(2). PMC: 7168640. DOI: 10.3390/pathogens9020076. View

Wasserman M, Palacios M, Grajales A, Wilson M, McDade C, Farkouh R . Comment on Gomez et. al. "Response to article by Wasserman et. al. (2018) 'Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico'". Hum Vaccin Immunother. 2019; 15(3):572-574. PMC: 6988870. DOI: 10.1080/21645515.2018.1558691. View

Perdrizet J, Lai Y, Williams S, Struwig V, Wasserman M . Retrospective Impact Analysis and Cost-Effectiveness of the Pneumococcal Conjugate Vaccine Infant Program in Australia. Infect Dis Ther. 2021; 10(1):507-520. PMC: 7954941. DOI: 10.1007/s40121-021-00409-7. View

Pugh S, Wasserman M, Moffatt M, Marques S, Reyes J, Prieto V . Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis. Infect Dis Ther. 2020; 9(2):305-324. PMC: 7237584. DOI: 10.1007/s40121-020-00287-5. View

Wasserman M, Palacios M, Grajales A, BaezRevueltas F, Wilson M, McDade C . Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico. Hum Vaccin Immunother. 2018; 15(3):560-569. PMC: 6605727. DOI: 10.1080/21645515.2018.1516491. View

Reyes J, LaRotta J, Castano N, Fletcher M, Wasserman M, Perdrizet J . Letter to the editor regarding "Budget impact analysis of pneumococcal conjugate vaccines in Colombia". Expert Rev Pharmacoecon Outcomes Res. 2021; 22(1):1-3. DOI: 10.1080/14737167.2022.1986006. View

Perdrizet J, Santana C, Senna T, Alexandre R, Sini de Almeida R, Spinardi J . Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants. Hum Vaccin Immunother. 2020; 17(4):1162-1172. PMC: 8018448. DOI: 10.1080/21645515.2020.1809266. View

Shafie A, Ahmad N, Naidoo J, Foo C, Wong C, Pugh S . Estimating the population health and economic impacts of introducing a pneumococcal conjugate vaccine in Malaysia- an economic evaluation. Hum Vaccin Immunother. 2020; 16(7):1719-1727. PMC: 7482775. DOI: 10.1080/21645515.2019.1701911. View

10.

Wilson M, Wasserman M, Jadavi T, Postma M, Breton M, Peloquin F . Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada. Infect Dis Ther. 2018; 7(3):353-371. PMC: 6098750. DOI: 10.1007/s40121-018-0206-1. View

11.

Perdrizet J, Santana C, Senna T, Alexandre R, Sini de Almeida R, Spinardi J . Reply letter to "response to article by Johnna Perdrizet et al." by Gomez and colleagues. Hum Vaccin Immunother. 2021; 18(1):1917237. PMC: 8942431. DOI: 10.1080/21645515.2021.1917237. View